Pharma Industry News

COVID-19 treatments drive Pfizer’s annual earnings up to $100bn

Written by David Miller

Big Pharma giant Pfizer’s annual earnings in 2022 reached $100bn, a considerable proportion of which came from its COVID-19 vaccine and antiviral treatment, Paxlovid.

The company’s $100.3bn earnings marked an all-time high for Pfizer, demonstrating a 23% increase on its earnings from 2021. Its profits for the year were $31bn, a 43% increase on the previous year.

Excluding its COVID-19 vaccine and treatment, Pfizer’s revenues grew by 2% over the entire year, and 5% in the fourth quarter.

read more

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]